Abelacimab, formerly known as MAA868, represents a groundbreaking approach to treating thrombosis. This antiplatelet agent is a specific monoclonal immunoglobulin that prevents the integrin αIIbβ3, a critical player https://www.targetmol.com/compound/abelacimab